The financing, which will back a novel type of cancer drug, is the largest of a series of startup fundings announced at the ...
The startup is developing a medicine that can very specifically degrade cancerous forms of EGFR, the target of an array of ...
Backed by more than a dozen prominent investors, the startup is advancing into human testing a drug it believes capable of ...
The buyout is a bet by Lilly on an increasingly popular drug target known as NLRP3 inflammasomes, which are implicated in an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback